Mark B. Faries, M.D.
Dr. Mark B. Faries is a board-certified general surgeon who currently practices at Cedars-Sinai Marina del Rey Hospital. He leads several clinical trials, including the Multicenter Selective Lymphadenectomy (II) trial, which enrolls thousands of patients throughout the world. The surgeon is also a member of the American Joint Committee on Cancer's Melanoma Staging Committee, the American Society of Clinical Oncology's Melanoma Guidelines Committee, and the Annals of Surgical Oncology's Editorial Board. Dr. Faries has directed clinical studies involving more than 6,000 patients and has received significant research funding from the National Cancer Institute. He was the first surgeon in California to conduct inguinal lymph node dissections using a minimally invasive technique. The physician founded a cellular immunotherapy laboratory that is certified by the FDA and has authored over 150 papers, abstracts, and book chapters.
At the moment, the general surgeon is the Associate Director of Surgical Oncology Experimental Therapeutics at Cedars-Sinai Department of Surgery at the Cedars-Sinai Medical Center. Dr. Mark B. Faries has over 20 professional experience. His subspecialties are melanoma and surgical oncology, excluding the breast. Over the years, the physician has been the recipient of numerous awards, including the Patients' Choice Award and Compassionate Doctor Recognition in 2017. Before practicing medicine in the state of California, Dr. Mark B. Faries had medical licenses for Connecticut and Pennsylvania. A new clinical trial the general surgeon is part of is the Minimally Invasive Groin Dissection for Melanoma (SAFE-MILND). The undergraduate school of Dr. Mark B. Faries is Haverford College.
Procedures Dr. Mark B. Faries Performs at Cedars-Sinai Marina del Rey Hospital
Education & Training
Cornell University - Weill Medical College, New York, NY
University of Pennsylvania School of Medicine, Philadelphia, PA
University of Pennsylvania Health System
John Wayne Cancer Institute, Santa Monica, CA
Memberships & Affiliations
Publications & Media
Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma
Anthony T Nguyen, Michael Luu, Vina P Nguyen, Omid Hamid, Mark B Faries, Nima M Gharavi, Diana J Lu, Jon Mallen-St Clair, Allen S Ho, Zachary S Zumsteg
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
Alexandra M. Adams, Robert C. Chick, Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale, Patrick M. McCarthy, Anne E. O'Shea, Phillip M. Kemp Bohan, Annelies T. Hickerson, Hyohyun Park, Amanda JoEllen Sloan, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Thomas Wagner, Mark B. Faries, George E. Peoples
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
Robert C. Chick, Mark B. Faries, Diane F. Hale, Phillip M. Kemp Bohan, Annelies T. Hickerson, Timothy J. Vreeland, John W. Myers, Jessica L. Cindass, Tommy A. Brown, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Guy T. Clifton, Hyohyun Park, Amanda J. Sloan, Thomas Wagner, George E. Peoples